EGFR and urinary bladder carcinoma: Furthermore, PA was validated <i>in vitro</i> to upregulate FABP6 and downregulate EGFR expression and suppress the bladder cancer progression <i>in vivo</i>.<h4>Conclusions</h4>PA, the active ingredient of GLQMW, can inhibit BC by inhibiting EGFR and upregulating FABP6.